UA80275C2 - Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants) - Google Patents

Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants) Download PDF

Info

Publication number: UA80275C2
Authority: UA; Ukraine
Prior art keywords: inhibitor; application according; protein; receptor; disease
Prior art date: 2002-03-22

Application number

UA20041008590A

Other languages

English (en)

Ukrainian (uk)

Inventor

Yolande Chvatchko

Alan Tedgui

Ziad Mallati

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-22

Filing date

2003-03-13

Publication date

2007-09-10

2003-03-13 Application filed by Applied Research Systems filed Critical Applied Research Systems

2007-09-10 Publication of UA80275C2 publication Critical patent/UA80275C2/uk

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 92
238000011282 treatment Methods 0.000 title claims abstract description 37
208000018262 Peripheral vascular disease Diseases 0.000 title claims abstract description 25
230000002265 prevention Effects 0.000 title claims abstract description 23
239000003814 drug Substances 0.000 claims abstract description 17
238000002360 preparation method Methods 0.000 claims abstract description 12
108090000623 proteins and genes Proteins 0.000 claims description 85
102000004169 proteins and genes Human genes 0.000 claims description 76
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
102000005962 receptors Human genes 0.000 claims description 41
201000010099 disease Diseases 0.000 claims description 35
239000005557 antagonist Substances 0.000 claims description 30
206010034576 Peripheral ischaemia Diseases 0.000 claims description 22
102000001708 Protein Isoforms Human genes 0.000 claims description 20
108010029485 Protein Isoforms Proteins 0.000 claims description 20
230000002093 peripheral effect Effects 0.000 claims description 20
210000001367 artery Anatomy 0.000 claims description 19
230000027455 binding Effects 0.000 claims description 17
108060003951 Immunoglobulin Proteins 0.000 claims description 16
102000018358 immunoglobulin Human genes 0.000 claims description 16
210000003141 lower extremity Anatomy 0.000 claims description 15
206010017711 Gangrene Diseases 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 14
208000030175 lameness Diseases 0.000 claims description 14
206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 13
230000004071 biological effect Effects 0.000 claims description 13
239000002202 Polyethylene glycol Substances 0.000 claims description 10
125000000539 amino acid group Chemical group 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
229920001223 polyethylene glycol Polymers 0.000 claims description 10
208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 9
125000004122 cyclic group Chemical group 0.000 claims description 9
102100035904 Caspase-1 Human genes 0.000 claims description 8
201000001320 Atherosclerosis Diseases 0.000 claims description 7
230000019491 signal transduction Effects 0.000 claims description 7
239000013598 vector Substances 0.000 claims description 7
208000033386 Buerger disease Diseases 0.000 claims description 6
201000002818 limb ischemia Diseases 0.000 claims description 6
125000000524 functional group Chemical group 0.000 claims description 5
239000013604 expression vector Substances 0.000 claims description 4
230000006698 induction Effects 0.000 claims description 4
108091026890 Coding region Proteins 0.000 claims description 3
238000011542 limb amputation Methods 0.000 claims description 2
108020001507 fusion proteins Proteins 0.000 claims 4
102000037865 fusion proteins Human genes 0.000 claims 4
108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 claims 4
102000003810 Interleukin-18 Human genes 0.000 abstract description 3
108090000171 Interleukin-18 Proteins 0.000 abstract description 3
235000018102 proteins Nutrition 0.000 description 56
230000000302 ischemic effect Effects 0.000 description 55
241000699670 Mus sp. Species 0.000 description 37
210000002683 foot Anatomy 0.000 description 32
230000000694 effects Effects 0.000 description 26
210000003414 extremity Anatomy 0.000 description 26
208000028867 ischemia Diseases 0.000 description 26
208000002193 Pain Diseases 0.000 description 22
238000000034 method Methods 0.000 description 22
210000004027 cell Anatomy 0.000 description 20
210000002414 leg Anatomy 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
230000003612 virological effect Effects 0.000 description 15
150000001413 amino acids Chemical group 0.000 description 14
238000002266 amputation Methods 0.000 description 14
230000000250 revascularization Effects 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 13
230000014509 gene expression Effects 0.000 description 13
230000001965 increasing effect Effects 0.000 description 12
210000005087 mononuclear cell Anatomy 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
208000024891 symptom Diseases 0.000 description 11
230000001684 chronic effect Effects 0.000 description 10
208000035475 disorder Diseases 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 9
230000010412 perfusion Effects 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
230000017531 blood circulation Effects 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
210000003462 vein Anatomy 0.000 description 8
208000031104 Arterial Occlusive disease Diseases 0.000 description 7
208000025865 Ulcer Diseases 0.000 description 7
210000001185 bone marrow Anatomy 0.000 description 7
239000000203 mixture Substances 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
208000037260 Atherosclerotic Plaque Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
208000021328 arterial occlusion Diseases 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
238000011161 development Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
210000003205 muscle Anatomy 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
230000010349 pulsation Effects 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
102000023732 binding proteins Human genes 0.000 description 5
108091008324 binding proteins Proteins 0.000 description 5
230000036770 blood supply Effects 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
230000003511 endothelial effect Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000035876 healing Effects 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
210000003371 toe Anatomy 0.000 description 5
231100000397 ulcer Toxicity 0.000 description 5
210000000689 upper leg Anatomy 0.000 description 5
206010003226 Arteriovenous fistula Diseases 0.000 description 4
108090000426 Caspase-1 Proteins 0.000 description 4
206010028851 Necrosis Diseases 0.000 description 4
208000012322 Raynaud phenomenon Diseases 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
230000009471 action Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
244000309466 calf Species 0.000 description 4
235000019504 cigarettes Nutrition 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
210000001105 femoral artery Anatomy 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000017074 necrotic cell death Effects 0.000 description 4
208000030613 peripheral artery disease Diseases 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000011002 quantification Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000010186 staining Methods 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000011477 surgical intervention Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
206010011703 Cyanosis Diseases 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
208000036376 Femoral artery occlusion Diseases 0.000 description 3
206010022562 Intermittent claudication Diseases 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000033115 angiogenesis Effects 0.000 description 3
238000002583 angiography Methods 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
238000004321 preservation Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
210000002820 sympathetic nervous system Anatomy 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
208000019553 vascular disease Diseases 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
206010024558 Lip oedema Diseases 0.000 description 2
208000007021 Lipedema Diseases 0.000 description 2
208000018501 Lymphatic disease Diseases 0.000 description 2
206010025282 Lymphoedema Diseases 0.000 description 2
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
206010033546 Pallor Diseases 0.000 description 2
208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
206010046996 Varicose vein Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
206010003230 arteritis Diseases 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001217 buttock Anatomy 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
208000024980 claudication Diseases 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
201000011384 erythromelalgia Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
235000015220 hamburgers Nutrition 0.000 description 2
230000036541 health Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
208000018555 lymphatic system disease Diseases 0.000 description 2
208000002502 lymphedema Diseases 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
231100000862 numbness Toxicity 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
210000003752 saphenous vein Anatomy 0.000 description 2
230000011664 signaling Effects 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
208000027185 varicose disease Diseases 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000000304 vasodilatating effect Effects 0.000 description 2
230000002455 vasospastic effect Effects 0.000 description 2
208000037997 venous disease Diseases 0.000 description 2
238000012800 visualization Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
208000035657 Abasia Diseases 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010062542 Arterial insufficiency Diseases 0.000 description 1
108700021072 Asp(5)- argipressin Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
-1 DNA or RNA Chemical class 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010016326 Feeling cold Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000001034 Frostbite Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
101001094636 Homo sapiens Blood vessel epicardial substance Proteins 0.000 description 1
101000608194 Homo sapiens Pyrin domain-containing protein 1 Proteins 0.000 description 1
101000595404 Homo sapiens Ribonucleases P/MRP protein subunit POP1 Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
208000035901 Ischaemic ulcer Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100039892 Pyrin domain-containing protein 1 Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
206010043595 Thrombophlebitis superficial Diseases 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
108010022164 acetyl-LDL Proteins 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000007720 allelic exclusion Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000008081 blood perfusion Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000001739 density measurement Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000002951 depilatory effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
IJRJBQGVWNVZSA-UHFFFAOYSA-N dilC18(3)(1+) Chemical compound CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C IJRJBQGVWNVZSA-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000012137 double-staining Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
210000003811 finger Anatomy 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
210000001255 hallux Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
102000054584 human Y acceptor Human genes 0.000 description 1
108700023876 human Y acceptor Proteins 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
206010062198 microangiopathy Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000007659 motor function Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000036562 nail growth Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000002559 palpation Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007119 pathological manifestation Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008180 pharmaceutical surfactant Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
238000013439 planning Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
210000003137 popliteal artery Anatomy 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000037152 sensory function Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000037974 severe injury Diseases 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
208000005198 spinal stenosis Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Marine Sciences & Fisheries (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Neurology (AREA)
Dermatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

UA20041008590A 2002-03-22 2003-03-13 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants) UA80275C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02100290		2002-03-22
PCT/EP2003/050061 WO2003080104A2 (en)	2002-03-22	2003-03-13	Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Publications (1)

Publication Number	Publication Date
UA80275C2 true UA80275C2 (en)	2007-09-10

Family

ID=28051827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041008590A UA80275C2 (en)	2002-03-22	2003-03-13	Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants)

Country Status (27)

Country	Link
US (2)	US9592267B2 (pt)
EP (1)	EP1487541B1 (pt)
JP (1)	JP4885424B2 (pt)
KR (1)	KR20050004809A (pt)
CN (1)	CN100540058C (pt)
AR (1)	AR039103A1 (pt)
AT (1)	ATE414556T1 (pt)
AU (1)	AU2003219162B2 (pt)
BR (1)	BRPI0308663B8 (pt)
CA (1)	CA2478855C (pt)
CY (1)	CY1108748T1 (pt)
DE (1)	DE60324777D1 (pt)
DK (1)	DK1487541T3 (pt)
EA (1)	EA008495B1 (pt)
ES (1)	ES2314191T3 (pt)
HR (1)	HRP20040758B1 (pt)
IL (2)	IL164211A0 (pt)
ME (1)	ME00548B (pt)
MX (1)	MXPA04009135A (pt)
NO (1)	NO336226B1 (pt)
PL (1)	PL207303B1 (pt)
PT (1)	PT1487541E (pt)
RS (1)	RS51755B (pt)
SI (1)	SI1487541T1 (pt)
UA (1)	UA80275C2 (pt)
WO (1)	WO2003080104A2 (pt)
ZA (1)	ZA200407022B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7914814B2 (en)	1997-09-17	2011-03-29	Strategic Science & Technologies, Llc	Topical delivery of arginine of cause beneficial effects
SK12942002A3 (sk) *	2000-02-10	2003-05-02	Abbott Laboratories	Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US9592267B2 (en)	2002-03-22	2017-03-14	Merck Serono Sa	Use of IL-18BP for treatment of peripheral vascular diseases
US7968684B2 (en) *	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
IL159670A0 (en) *	2003-12-31	2004-06-01	Yeda Res & Dev	Use of il-18 binding protein in inflammations
JP2007532697A (ja) *	2004-04-19	2007-11-15	ストラテジックサイエンスアンドテクノロジーズ，エルエルシー	局所的血流増大の有益な効果
US9226909B2 (en)	2004-04-19	2016-01-05	Strategic Science & Technologies, Llc	Beneficial effects of increasing local blood flow
CA2609060C (en)	2005-06-03	2014-07-15	Urs Weber	Production of recombinant il-18 binding protein
PT1891088E (pt)	2005-06-10	2011-12-19	Ares Trading Sa	Processo para a purificação da proteína de ligação il-18
WO2009108890A1 (en)	2008-02-27	2009-09-03	Biomet Biologics, Llc	Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en)	2008-02-27	2014-06-17	Biomet Biologics, Llc	Methods and compositions for delivering interleukin-1 receptor antagonist
US12138268B2 (en)	2009-06-24	2024-11-12	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
CN102481275B (zh)	2009-06-24	2014-07-23	战略科学技术有限公司	含有布洛芬的表面组合物
US11684624B2 (en)	2009-06-24	2023-06-27	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
EP2445493A1 (en)	2009-06-24	2012-05-02	Strategic Science & Technologies, LLC	Topical composition containing naproxen
JP5844258B2 (ja)	2009-08-27	2016-01-13	バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーＢｉｏｍｅｔＢｉｏｌｏｇｉｃｓ，Ｌｌｃ	インターロイキン−１受容体アンタゴニストの生産のための植込み型装置
CN102639700A (zh)	2009-09-30	2012-08-15	哈佛大学校长及研究员协会	通过调节自噬增强基因产物调节自噬的方法
KR101603001B1 (ko)	2010-08-25	2016-03-11	에프. 호프만-라 로슈 아게	Il-18r1에 대한 항체 및 그의 용도
EP2658551B1 (en)	2010-12-29	2020-07-01	Strategic Science & Technologies, LLC	Treatment of erectile dysfunction and other indications
CN103442723A (zh)	2010-12-29	2013-12-11	战略科学与技术有限责任公司	治疗变态反应和其它适应症的系统和方法
US9376489B2 (en)	2012-09-07	2016-06-28	Novartis Ag	IL-18 binding molecules
US9758806B2 (en)	2013-03-15	2017-09-12	Biomet Biologics, Llc	Acellular compositions for treating inflammatory disorders
US9878011B2 (en)	2013-03-15	2018-01-30	Biomet Biologics, Llc	Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en)	2013-03-15	2014-09-18	Biomet Biologics, Llc	Treatment of collagen defects using protein solutions
US10143725B2 (en)	2013-03-15	2018-12-04	Biomet Biologics, Llc	Treatment of pain using protein solutions
US10208095B2 (en)	2013-03-15	2019-02-19	Biomet Manufacturing, Llc	Methods for making cytokine compositions from tissues using non-centrifugal methods
US9895418B2 (en)	2013-03-15	2018-02-20	Biomet Biologics, Llc	Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en)	2013-03-15	2018-04-24	Biomet Biologics, Llc	Methods and non-immunogenic compositions for treating inflammatory disorders
WO2015081253A1 (en)	2013-11-26	2015-06-04	Biomet Biologics, Llc	Methods of mediating macrophage phenotypes
US10441635B2 (en)	2014-11-10	2019-10-15	Biomet Biologics, Llc	Methods of treating pain using protein solutions
CN107660150B (zh) *	2015-03-05	2023-10-24	Ab2生物股份有限公司	Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US9763800B2 (en)	2015-03-18	2017-09-19	Biomet C. V.	Implant configured for hammertoe and small bone fixation
BR112022020256A2 (pt)	2020-04-09	2023-01-03	Aprilbio Co Ltd	anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5877197A (en) *	1996-12-16	1999-03-02	Karanewsky; Donald S.	C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) *	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) *	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) *	1998-09-01	2000-03-09	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin 18-binding protein
EP1101772B1 (en) *	1999-11-16	2009-01-21	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Antibody specific to interleukin 18 precursor
CA2407895C (en) *	2000-05-05	2012-12-18	Applied Research Systems Ars Holding N.V.	Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
PE20011350A1 (es) *	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002032374A2 (en) *	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders
US9592267B2 (en)	2002-03-22	2017-03-14	Merck Serono Sa	Use of IL-18BP for treatment of peripheral vascular diseases

2003
- 2003-03-13 US US10/508,574 patent/US9592267B2/en not_active Expired - Lifetime
- 2003-03-13 ES ES03714958T patent/ES2314191T3/es not_active Expired - Lifetime
- 2003-03-13 SI SI200331457T patent/SI1487541T1/sl unknown
- 2003-03-13 RS YU81504A patent/RS51755B/sr unknown
- 2003-03-13 UA UA20041008590A patent/UA80275C2/uk unknown
- 2003-03-13 EP EP03714958A patent/EP1487541B1/en not_active Expired - Lifetime
- 2003-03-13 AU AU2003219162A patent/AU2003219162B2/en not_active Expired
- 2003-03-13 JP JP2003577930A patent/JP4885424B2/ja not_active Expired - Lifetime
- 2003-03-13 PL PL372398A patent/PL207303B1/pl unknown
- 2003-03-13 MX MXPA04009135A patent/MXPA04009135A/es active IP Right Grant
- 2003-03-13 WO PCT/EP2003/050061 patent/WO2003080104A2/en not_active Ceased
- 2003-03-13 KR KR10-2004-7014401A patent/KR20050004809A/ko not_active Ceased
- 2003-03-13 PT PT03714958T patent/PT1487541E/pt unknown
- 2003-03-13 ME MEP-2008-679A patent/ME00548B/me unknown
- 2003-03-13 IL IL16421103A patent/IL164211A0/xx unknown
- 2003-03-13 DK DK03714958T patent/DK1487541T3/da active
- 2003-03-13 DE DE60324777T patent/DE60324777D1/de not_active Expired - Lifetime
- 2003-03-13 CN CNB038116510A patent/CN100540058C/zh not_active Expired - Lifetime
- 2003-03-13 AT AT03714958T patent/ATE414556T1/de active
- 2003-03-13 HR HRP20040758AA patent/HRP20040758B1/hr not_active IP Right Cessation
- 2003-03-13 BR BRPI0308663A patent/BRPI0308663B8/pt not_active IP Right Cessation
- 2003-03-13 CA CA2478855A patent/CA2478855C/en not_active Expired - Lifetime
- 2003-03-13 EA EA200401240A patent/EA008495B1/ru not_active IP Right Cessation
- 2003-03-21 AR ARP030101000A patent/AR039103A1/es not_active Application Discontinuation
2004
- 2004-09-02 ZA ZA200407022A patent/ZA200407022B/en unknown
- 2004-09-22 IL IL164211A patent/IL164211A/en active IP Right Grant
- 2004-10-20 NO NO20044459A patent/NO336226B1/no not_active IP Right Cessation
2009
- 2009-02-05 CY CY20091100132T patent/CY1108748T1/el unknown
2010
- 2010-06-01 US US12/791,052 patent/US9566313B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO20044459L (no)	2004-10-20
HK1075422A1 (zh)	2005-12-16
BRPI0308663B1 (pt)	2019-07-16
RS51755B (sr)	2011-12-31
HRP20040758A2 (en)	2005-02-28
ME00548B (me)	2011-10-10
US9592267B2 (en)	2017-03-14
EP1487541A2 (en)	2004-12-22
ZA200407022B (en)	2006-06-28
IL164211A (en)	2011-07-31
CN1655845A (zh)	2005-08-17
BRPI0308663B8 (pt)	2021-05-25
RS81504A (sr)	2006-12-15
WO2003080104A2 (en)	2003-10-02
US9566313B2 (en)	2017-02-14
CA2478855A1 (en)	2003-10-02
CN100540058C (zh)	2009-09-16
JP4885424B2 (ja)	2012-02-29
CA2478855C (en)	2013-12-17
AR039103A1 (es)	2005-02-09
EA008495B1 (ru)	2007-06-29
AU2003219162B2 (en)	2008-01-03
IL164211A0 (en)	2005-12-18
EP1487541B1 (en)	2008-11-19
AU2003219162A1 (en)	2003-10-08
SI1487541T1 (sl)	2009-02-28
MXPA04009135A (es)	2004-12-07
PL372398A1 (en)	2005-07-25
HRP20040758B1 (hr)	2012-10-31
NO336226B1 (no)	2015-06-22
ATE414556T1 (de)	2008-12-15
CY1108748T1 (el)	2014-04-09
WO2003080104A3 (en)	2004-03-04
US20060233799A1 (en)	2006-10-19
EA200401240A1 (ru)	2005-02-24
PL207303B1 (pl)	2010-11-30
PT1487541E (pt)	2008-12-10
DE60324777D1 (de)	2009-01-02
JP2005520852A (ja)	2005-07-14
KR20050004809A (ko)	2005-01-12
BR0308663A (pt)	2005-01-25
DK1487541T3 (da)	2009-01-19
ES2314191T3 (es)	2009-03-16
US20100291028A1 (en)	2010-11-18

Publication	Publication Date	Title
US9566313B2 (en)	2017-02-14	Method of treating peripheral vascular diseases using IL-18 inhibitors
CA2407895C (en)	2012-12-18	Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2001267390A1 (en)	2002-02-07	Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2004308763A1 (en)	2005-07-14	Use of IL-18 binding protein in inflammations
HK1075422B (en)	2010-05-14	Use of il-18 inhibitors in the manufacture of medicaments
AU2005211606B2 (en)	2007-02-22	Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
HK1094909B (en)	2013-02-15	Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis